 Optimal dose neuroleptic acute schizophrenia controlled study neuroleptic threshold haloperidol dose individual determination neuroleptic threshold NT haloperidol patients schizophrenia schizoaffective disorder Research Diagnostic Criteria doses mean mg/d weeks patients unavailable follow-up subsequent randomization non-responding patient randomization patients double-blind dosage haloperidol times mean mg/d NT dosage mean mg/d weeks patients NT dosages haloperidol trial dosages patients improvement measures psychosis declines measures hostility dosages lead significant increases extrapyramidal side effects